Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dihon

China flag thumb

Chinese biotech claims 90% cure rate for CAR-T therapy

Innovative Cellular Therapeutics presents ‘stellar’ immunotherapy data

Bayer symbol

Bayer eyes liver cancer indication for Stivarga

New trial data shows improvement in overall survival in HCC patients

- PMLiVE

Japanese approvals for GSK, AZ and Bayer

MHLW gives Nucala, Tagrisso and Xofigo the green light

- PMLiVE

Bayer appoints Dr Michael Preuss as new comms head

He takes over from Dr Herbert Heitmann

- PMLiVE

IQWiG unimpressed with Cosentyx in two new indications

Concludes Novartis drug has no added benefit in ankylosing spondylitis or psoriatic arthritis

- PMLiVE

Women’s well-being needs are broader than health

Merck event hears how women’s and government priorities are often mismatched

Bayer symbol

Bayer picks strategy head for top post

Werner Baumann will take over from Dr Marijn Dekkers

Bayer symbol

Bayer gets first approval for Kogenate upgrade Kovaltry

First worldwide licence for the haemophilia treatment

- PMLiVE

Sustainable solutions

Bayer's Alex Moscho on working towards long-term answers in healthcare

How Bayer transformed its approach to digital

Head of digital development Jessica Federer on how the company built digital into its DNA

12 Challenges Big Pharma Faces in China

Published in eyeforpharma 16 November by Rachel Howard

Research Partnership

- PMLiVE

Bayer forms JV with gene editing firm CRISPR

$300m investment to find new therapies for blood disorders, blindness and congenital heart disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links